Holds Litecoin tokens as a reserve asset and writes covered call options on some holdings, while developing drug candidates for nononcologic diseases and assessing cancer drugs for potential licensing or sale.
10-K for FY2026, filed Sep 28, 2026Lite Strategy, Inc. (Nasdaq: LITS) is a pharmaceutical company that has historically developed novel and differentiated cancer therapies.…View ↗
We enter into contracts with GSR Markets Ltd (GSR Markets), an affiliate of GSR Strategies LLC (GSR or Asset Manager), in which we write…View ↗
We are currently evaluating voruciclib in a pre-clinical development program for nononcologic diseases and commenced these activities in…View ↗
Zandelisib is an oral, once-daily, selective PI3Kδ inhibitor that was being developed for the treatment of indolent B-cell lymphomas. In…View ↗
No. It lost $71.2M in FY2026.
10-K for FY2026, filed Sep 28, 2026
10-Q for Q1 FY2027, filed Nov 5, 2026
$16MView ↗
From cancer drug development to a Litecoin treasury
The earlier report described a clinical-stage company developing cancer therapies. The latest report centers on holding Litecoin as a reserve asset, while pursuing pre-clinical work in nononcologic diseases and assessing drug candidates for licensing or sale.
10-K for FY2023, filed Sep 26, 2023 10-K for FY2026, filed Sep 28, 2026MEI Pharma, Inc. (Nasdaq: MEIP) is a clinical-stage pharmaceutical company committed to developing novel and differentiated cancer…View ↗
Lite Strategy, Inc. (Nasdaq: LITS) is a pharmaceutical company that has historically developed novel and differentiated cancer therapies.…View ↗
On August 5, 2025, we announced the commencement of our primary reserve asset and implementation strategy built on a digital asset…View ↗
We are currently evaluating voruciclib in a pre-clinical development program for nononcologic diseases and commenced these activities in…View ↗
Zandelisib is an oral, once-daily, selective PI3Kδ inhibitor that was being developed for the treatment of indolent B-cell lymphomas. In…View ↗
Loading...